Mixed Lineage Kinase Domain-Like Protein (MLKL): From Mechanisms to Therapeutic Opportunities

混合谱系激酶结构域样蛋白(MLKL):从机制到治疗机遇

阅读:1

Abstract

Lytic forms of regulated cell death (RCD) rely on the activation and recruitment of executioner proteins. The mixed lineage kinase domain-like protein (MLKL) acts as the executioner in the necroptosis pathway, transitioning from an inactive to active state through phosphorylation, oligomerization, membrane recruitment, and membrane insertion, ultimately forming membrane hotpots. These mechanisms involve protein-protein interactions between receptor-interacting protein kinase 3 (RIPK3) and MLKL, MLKL phosphorylation, protein-protein interactions between MLKL and MLKL, and MLKL-lipid interactions. In this review, the specificity of MLKL activation mechanisms is discussed across different species and describe the processes by which MLKL transitions from an auto-inhibited to a membrane-embedded state. The opportunities are further explored for targeting MLKL, including small molecule inhibitors and functionally interacting proteins.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。